Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference
Eledon Pharmaceuticals (Nasdaq: ELDN) will present at the Guggenheim Second Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 10:30 a.m. ET (7:30 a.m. PT). David-Alexandre C. Gros, M.D., CEO, will deliver the presentation. A live webcast will be available with a replay posted on the company website under Events for registered users.
Eledon Pharmaceuticals (Nasdaq: ELDN) parteciperà al Guggenheim Second Annual Healthcare Innovation Conference il mercoledì 12 novembre 2025 alle 10:30 ET (7:30 PT). David-Alexandre C. Gros, M.D., CEO, terrà la presentazione. Una diretta webcast sarà disponibile con una replica pubblicata sul sito web dell'azienda nella sezione Eventi per gli utenti registrati.
Eledon Pharmaceuticals (Nasdaq: ELDN) se presentará en la Conferencia Guggenheim sobre Innovación en Salud, Segunda Edición el miércoles 12 de noviembre de 2025 a las 10:30 a.m. ET (7:30 a.m. PT). David-Alexandre C. Gros, M.D., CEO, realizará la presentación. Se dispondrá de una transmisión en directo con una repetición publicada en el sitio web de la empresa en la sección Eventos para usuarios registrados.
Eledon Pharmaceuticals (Nasdaq: ELDN)는 Guggenheim 제2회 연례 헬스케어 혁신 컨퍼런스에서 2025년 11월 12일 수요일 오전 10:30 ET(오전 7:30 PT)에 발표할 예정입니다. David-Alexandre C. Gros, M.D., CEO가 발표를 진행합니다. 라이브 생중계가 제공되며, 등록 사용자를 위한 Events 섹션에 재생본이 회사 웹사이트에 게시됩니다.
Eledon Pharmaceuticals (Nasdaq: ELDN) sera présente au Guggenheim Second Annual Healthcare Innovation Conference le mercredi 12 novembre 2025 à 10h30 HE (7h30 PT). David-Alexandre C. Gros, M.D., PDG, effectuera la présentation. Une webdiffusion en direct sera disponible, avec une rediffusion publiée sur le site de l'entreprise dans la section Événements pour les utilisateurs enregistrés.
Eledon Pharmaceuticals (Nasdaq: ELDN) wird beim Guggenheim Second Annual Healthcare Innovation Conference am Mittwoch, dem 12. November 2025 um 10:30 Uhr ET (7:30 Uhr PT) auftreten. David-Alexandre C. Gros, M.D., CEO, wird die Präsentation halten. Eine Live-Übertragung wird verfügbar sein, mit einer Wiedergabe, die auf der Website des Unternehmens unter Events für registrierte Nutzer veröffentlicht wird.
Eledon Pharmaceuticals (ناسداك: ELDN) ستقدم في مؤتمر Guggenheim الثاني للابتكار في الرعاية الصحية في يوم الأربعاء 12 نوفمبر 2025 الساعة 10:30 صباحًا بتوقيت شرق الولايات المتحدة (7:30 صباحًا بتوقيت المحيط الهادئ). سيوجه الدكتور ديفيد-ألكسندر جرو، الرئيس التنفيذي، العرض. سيتوفر بث مباشر مع إعادة عرض منشورة على موقع الشركة على الويب في قسم الأحداث للمستخدمين المسجلين.
- None.
- None.
IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will present at the upcoming Guggenheim Second Annual Healthcare Innovation Conference on Wednesday, November 12, 2025, at 10:30 a.m. ET (7:30 a.m. PT).
To register in advance for the webcast, sign up here.
A webcast replay will be accessible following the live session on the Company’s website under Events.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
Source: Eledon Pharmaceuticals